Zim Laboratories logo

Zim Laboratories financials and balance sheet

NSE: ZIMLABBSE: 541400Pharmaceuticals & BiotechnologySmall Cap

Last close ₹126.22down ₹5.90 (4.47%)BSE ₹126.60

Share price at the NSE close on 23 Oct 2026. Previous close ₹132.12.

52-week range of traded prices to 23 Oct 2026
₹59.31Low, 30 Mar 2026₹159.81High, 12 Oct 2026
Market cap
₹677 Cr1,933rd largest listed
P/E
183.2
P/B
2.3
Dividend yield
Nonein the last 12 months
ROE
1.3%
ROCE
1.8%
Debt to equity
0.42
Volume, NSE
1,16,71445.7% delivered

9 years at a glance

Consolidated: the company and its subsidiaries together. ₹ crore, years to March.Zim Laboratories annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
Peak revenue ₹399 Cr, year to Mar 2023

Operating and net margin, per cent

  • Operating margin
  • Net margin

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 3.5% of operating profit in the first full year.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue374
  2. Materials and goods−165
  3. Employee costs−64
  4. Other expenses−115
  5. Operating profit30
  6. Depreciation−20
  7. Other income+11
  8. One-off items0.0
  9. Finance costs−13
  10. Profit before tax8.2
  11. Tax−2.4
  12. Net profit5.8

What the company owns

  • Plant, investments and other assets₹293 Cr
  • Receivables₹109 Cr
  • Inventory₹94 Cr
  • Cash and bank₹43 Cr

What pays for it: net worth and liabilities

  • Net worth₹296 Cr
  • Borrowings₹123 Cr
  • Owed to suppliers₹73 Cr
  • Other liabilities₹47 Cr

Profit and loss

Consolidated, ₹ crore, years to March.Zim Laboratories quarterly results

₹ croreMar 2018Mar 2019Filed 24 MayMar 2020Filed 3 JunMar 2021Filed 31 MayMar 2022Filed 25 MayMar 2023Filed 7 JunMar 2024Filed 14 MayMar 2025Filed 12 JunMar 2026Filed 19 May
Revenue from operations274335278307333399367379374
239293255268292347326335344
Materials and goods bought141160143159160199171168165
Employee costs–4851364049536164
Other expenses–8661739298101107115
Operating profit before depreciation354223404152414430
Operating margin12.7%12.5%8.1%12.9%12.3%13.0%11.2%11.5%8.0%
Materials, % of revenue–47.6%51.5%51.6%48.1%49.9%46.7%44.3%44.2%
Employee costs, % of revenue–14.4%18.5%11.6%12.0%12.4%14.5%16.0%17.1%
Other expenses, % of revenue–25.5%21.8%23.8%27.6%24.7%27.6%28.1%30.7%
Depreciation and amortisation101114161617162020
Operating profit after depreciation25318242535252410
Other income3252465611
Finance costs91113118671113
Profit before one-off items and tax1922015213524188
One-off items600−500000
Profit before tax2522010213524188
67−33611662
191537152417126
Other comprehensive income–00001002
Total comprehensive income–1647152517128
Net margin7.0%4.6%1.2%2.4%4.4%6.1%4.7%3.2%1.6%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the year to Mar 2018 they do not, so they are left blank.

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2019Filed 24 MayMar 2020Filed 3 JunMar 2021Filed 31 MayMar 2022Filed 25 MayMar 2023Filed 7 JunMar 2024Filed 14 MayMar 2025Filed 12 JunMar 2026Filed 19 May
151154161176200239252296
151154161176200239252296
Share capital1616161649494954
Reserves135138145159152190204243
Belonging to outside owners of subsidiaries000–0000
6277665160106112123
155143142146111159166190
2228222030495353
Total assets328325325342342447472539
132140133129151219241264
197186192212191228231276
Net debt59735846529611080
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the year to Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2021Filed 31 MayMar 2022Filed 25 MayMar 2023Filed 7 JunMar 2024Filed 14 MayMar 2025Filed 12 JunMar 2026Filed 19 May
31.949.237.516.341.249.5
33.049.644.718.940.153.3
−8.26.6−12.8−26.8−10.416.0
Receivables−9.6−16.3−5.4−4.7−8.01.1
Inventories2.0−20.921.6−27.6−5.2−7.3
Payables−1.116.2−22.84.17.13.4
Other working capital0.427.6−6.21.3−4.318.7
Tax paid−1.1−0.4−7.1−2.61.1−3.7
Capital spending6.515.236.773.940.844.4
Free cash flow25.434.00.9−57.60.45.1
−5.9−14.6−36.2−73.0−39.9−56.3
−26.0−33.00.559.5−9.128.2
Dividends paid0.00.00.00.00.00.0
Shares bought back0.00.00.00.00.00.0
Shares issued0.10.00.00.00.035.0
Net change in cash0.01.71.92.8−7.921.4
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2018, Mar 2019 and Mar 2020.

Per share

Consolidated, ₹ per share, years to March.

₹ per shareMar 2018Mar 2019Filed 24 MayMar 2020Filed 3 JunMar 2021Filed 31 MayMar 2022Filed 25 MayMar 2023Filed 7 JunMar 2024Filed 14 MayMar 2025Filed 12 JunMar 2026Filed 19 May
₹7.91₹3.17₹0.68₹1.50₹2.99₹5.01₹3.54₹2.50₹1.19
As stated that year₹23.74₹9.52₹2.03₹4.50₹8.96₹5.01₹3.54₹2.50₹1.19
₹7.86₹3.15₹0.68₹1.50₹2.99₹5.01₹3.54₹2.50₹1.19
–₹31.25₹31.69₹32.99₹36.06₹41.12₹49.00₹51.77₹55.36
Shareholder yield–––−0.1%0.0%0.0%0.0%0.0%−10.9%
Market cap at the year end (₹ crore)–20291118260352463392322
Every year is restated for later splits and bonuses, so they do not break the line. The figure the company stated that year is under each line it differs from.

Ratios

Consolidated, years to March.Zim Laboratories PE ratio and valuation

RatioMar 2018Mar 2019Filed 24 MayMar 2020Filed 3 JunMar 2021Filed 31 MayMar 2022Filed 25 MayMar 2023Filed 7 JunMar 2024Filed 14 MayMar 2025Filed 12 JunMar 2026Filed 19 May
Revenue growth–22.3%−17.2%10.6%8.5%19.5%−7.8%3.2%−1.2%
Operating profit growth–20.8%−46.2%75.8%3.1%26.9%−20.5%5.8%−31.4%
Net profit growth–−19.7%−78.5%122.0%98.8%67.9%−29.4%−29.5%−52.0%
Earnings per share growth–−59.9%−78.7%121.7%99.1%67.7%−29.3%−29.4%−52.4%
–10.2%2.2%4.7%8.6%13.0%7.9%5.0%2.1%
––−8.0 pts2.5 pts4.0 pts4.3 pts−5.1 pts−2.9 pts−2.8 pts
From the net margin––−7.5 pts2.2 pts3.9 pts3.5 pts−3.0 pts−2.5 pts−2.5 pts
From asset turnover––−0.4 pts0.5 pts0.5 pts2.0 pts−2.0 pts−0.6 pts−0.2 pts
From borrowing––0.0 pts−0.2 pts−0.4 pts−1.2 pts−0.1 pts0.2 pts0.0 pts
Return on capital employed–14.3%3.6%10.6%11.0%13.3%7.4%6.5%2.4%
Cash conversion–––435.3%338.2%153.6%94.4%338.3%848.5%
Interest cover2.72.90.62.23.06.23.72.10.8
Debt to equity–0.410.500.410.290.300.450.440.42
Receivable days–10189869887100103106
Inventory days–12614412517199173188207
Payable days–165168149185107133151161
Cash conversion cycle, days–6365628579140140152
Working capital days–8511610210299128129120
Asset turnover–1.020.850.951.001.170.930.830.74
Assets per rupee of net worth–2.172.142.071.981.821.801.871.84
Sales per rupee of plant–3.372.593.053.283.842.342.392.39
Capital spending to depreciation–––0.410.952.104.632.032.22
Plant being built, % of plant in use–7.8%4.4%4.5%5.0%17.2%15.0%27.8%37.6%
No balance sheet is on record for the year to Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
1.2%
Cash from operations against operating profit
165.1%
Measure10 years5 years3 years
Revenue growth, yearly rate–4.0%−2.1%
Profit growth, yearly rate–−4.4%−37.9%
Return on equity, average–7.3%5.0%
Return on capital employed, average–8.1%5.4%
Operating margin, average11.4%11.2%10.3%
Net margin, average3.9%4.0%3.2%
Asset turnover, average–0.930.83
Cash conversion cycle, days, average–119144
Interest cover, average2.73.12.2
Debt to equity, average–0.380.44

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations19410750
Cash from investing−220−169−56
Cash from financing467928
Capital spending21115944
Dividends paid000
Shares bought back000
Shares issued for cash353535
Borrowings raised1237825
Borrowings repaid1195215

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9–––796456
Altman Z-scorePublished threshold 1.81–2.762.052.403.083.963.162.852.44
Beneish M-scorePublished threshold −1.78–––−2.75−2.85−2.24−2.46−2.65−2.79
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–––−5.74−6.036.7718.772.382.50
Cash from operations to profit, 3 yearsPublished threshold 0.7 times–––––2.561.831.763.03
Receivables growth less revenue growthOur threshold 0 percentage points––−9.85−4.2615.39−13.1312.973.583.20
Inventory growth less cost-of-goods growthOur threshold 0 percentage points––12.69−14.4437.44−52.6765.098.509.92
Other current assets growth less revenue growthOur threshold 5 per cent of revenue––4.38−0.19−4.32−1.980.36−0.09−1.56
Assets under construction, years of additionsOur threshold 2 years of additions––0.210.500.300.920.342.053.25
Effective tax ratePublished threshold 17.16 per cent23.3630.49−4,705.5428.4830.8530.8927.0532.4528.91
Tax charged less tax paid, % of profitOur threshold 10 percentage points––––28.8110.6716.1226.48−16.55
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
8 Oct 2026CARE Ratings Limited (opens in a new tab)Non-fund-based - ST-BG/LCCARE A3Review, Re-affirm12
8 Oct 2026CARE Ratings Limited (opens in a new tab)Fund-based - LT-Term LoanCARE BBBReview, Re-affirmNegative46.98
8 Oct 2026CARE Ratings Limited (opens in a new tab)Fund-based - LT-Cash CreditCARE BBBReview, Re-affirmNegative80.50
17 Feb 2026Acuite Ratings & Research LimitedBank Loan RatingsACUITE A3+Review, Re-affirm16
17 Feb 2026Acuite Ratings & Research LimitedBank Loan RatingsACUITE BBBReview, Re-affirmStable150.23
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.